Clinical Trial: This is a Phase 1, Randomized, Single-blind, Placebo-controlled Study to Assess the Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of BEAM-103 in Healthy Subjects

U.S., Dec. 27 -- ClinicalTrials.gov registry received information related to the study (NCT07304791) titled 'This is a Phase 1, Randomized, Single-blind, Placebo-controlled Study to Assess the Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of BEAM-103 in Healthy Subjects' on Sept. 29.

Brief Summary: The purpose of this Phase I single ascending dose study is to evaluate the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of BEAM-103 in healthy subjects between the ages of 18 and 55. The main questions the study aims to answer are:

* Safety and tolerability of BEAM-103

* The pharmacokinetic (PK) profile and pharmacodynamic (PD) characteristics of EAM-103

* The effect of BEAM-103 on hematologic parameters

* To assess th...